Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors"

Affiliations

¹ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
² Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Electronic address: sakakoji@med.nagoya-u.ac.jp.
³ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.
⁴ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Respiratory Medicine, Handa City Hospital, Handa, Aichi, Japan.
⁵ Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
⁶ Department of Respiratory Medicine, Handa City Hospital, Handa, Aichi, Japan.
⁷ Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.

Comment

Jun Fukihara et al. Clin Lung Cancer. 2020 May.

. 2020 May;21(3):e205.

doi: 10.1016/j.cllc.2019.11.013. Epub 2019 Dec 2.

¹ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
² Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Electronic address: sakakoji@med.nagoya-u.ac.jp.
³ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.
⁴ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Respiratory Medicine, Handa City Hospital, Handa, Aichi, Japan.
⁵ Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
⁶ Department of Respiratory Medicine, Handa City Hospital, Handa, Aichi, Japan.
⁷ Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.

No abstract available

Comment on

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Fukihara J, et al. Clin Lung Cancer. 2019 Nov;20(6):442-450.e4. doi: 10.1016/j.cllc.2019.07.006. Epub 2019 Aug 1. Clin Lung Cancer. 2019. PMID: 31446020
Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer.
Suresh K, Naidoo J. Suresh K, et al. Clin Lung Cancer. 2020 May;21(3):e169-e170. doi: 10.1016/j.cllc.2019.10.009. Epub 2019 Nov 6. Clin Lung Cancer. 2020. PMID: 31787546 No abstract available.